1. Most Discussed
  2. Gainers & Losers
PTD 0.0¢

big rise on announcement?

  1. Redbeard.

    143 Posts.

    07-FEB-2003 FRI 08:48 PEPTECH LIMITED FAX NO. 98898088 P, 01
    ABN 118 002 951 S77
    Att Company Announcements Office
    FAX NUMBEk 1300 300 021 llllll~IYlllllllllllllalllil~lillllYIU
    DATE: February 7,2003
    NUMBER OF PAGES: 2 (incl this page)
    FROM: Niall Henderson
    Peptech Limited
    Suite 2, Level 3, Building A, 11 Ta:l.avera Road
    North Ryde, NSW 2113, Australia Nor
    (Locked Bag 2053, North Ryde NSW 1670)
    Tel: +61(0)2 9870 8788 Fax: +61 ('0)2 9889 8088
    E-mail: [email protected],nwtacb.com
    Dear Sir
    Attached is an announcement for release to the market.
    Yours sincerely
    Niall Henderson
    Company Secretary
    07-FEB-2003 FRI 08:49 PEPTECH LIMITED . . -- .- . FAX NO. 98898088 P, 02
    ASX Announcement and Media Release
    Date: 7 February 2003
    Domantis Limited, the company in which Peptech will hold a 36.1 % intwest, made the following
    announcement yesterday in relation to the granting of a patent in the USA in pioneering protein selection
    "Domantis has Exclusive Rights to Pioneering Protein Selection Technology which Gains US
    Cambridge, UKand USA, 6 February, 2003... Domantis Limited, tho leading Domain Antibody (dAbJ
    drug discovery company, has strengthened its technologyposition for I'he selection ofantibodies and
    antibody fragments following the grant of US Patent Number 8,489,10,:3. Domantis has field-exclusive
    rights from the UKs Medical Research Council (MRCJ to thrs pioneerirlg emulsion technology, which
    offers significant advantages over existing methodologias.
    The emulsion technology enables users to extract specific genes which encode proteins with desirable
    activities from large pools of gene sequences. For the isolation of anti1:rodie.s this is traditionally achieved
    by animal immunization or by in vitro selection technologies such as pi$age display. Unlike phage
    selection, the new technique does not use bacteria or cells, or require repetitive and time-consuming
    laboratorytasks such as centrifugation and overnight culture. The emi.llsion technology has the potential
    to be automated for high throughput efficiency and maximum canvenienm.
    Domantis Chief Scientific Officer and CO-Founder /an Tomiinson said, 'This technology takes us one step
    closer to the ideal scenario of entering a chosen antibody target at on(!, end of a machine and retrieving a
    binding dAb at the other. The invention underlines the quality of the pioneering work undertaken at the
    Medical Research Council's Laboratory of Molecular Biology (MRC-LMBJ and Centre for Protein
    Engineering (MRC-CPEJ in Cambridge, UK, where the emulsion technology is being researched and
    developed. Should the work that Domantis is funding continue on track we plan to integrate the
    technology into our drug discovery efforts and commercialise it througlh licensing deals and development
    of automated antibody selection instrumentation.'
    The new technology is based on a water-in-oil emulsion which compslrtmentalises genes and their
    products into an entity which behaves like an arfificialceil. It was invmtad by DrsAndrew Griffiths and
    Dan Tawfik of the MRC-LMB, both of whom are consultants to Domantis. The grant of the US patent
    complements the corresponding UKpalent (UK-2342094) and an Awtralian patent (AU736836). which
    were granted in October 2002 and November 2001 respectively The patent family is managed by the
    MRC. Domantis has exclusive commercial rights to this intellectual pmperty for the fields of antibodies,
    antibody fragments and T mllreceptws. MRCretains rights to license outside of these fields.
    For further information please contact:
    Ph (02) 9870 8788
    PEPTECH LIMITED ~ -. . . -~ ~ . .
    Ph (02) 9870 8788

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.